nach oben

Strahlentherapie und Onkologie

Erschienen in:

15.09.2022 | Original Article

Dose–effect relationship between dose–volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study

verfasst von: Tianyang Ke, Jinbao Wang, Ning Zhang, Hongfu Zhao, Xin Guo, Zhipeng Zhao, Zhuang Mao, Guanghui Cheng

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the dose–effect relationship between the dose–volume parameters of residual gross tumor volume (GTV_res) and clinical prognosis in MRI image-guided adaptive brachytherapy (IGABT) of patients with locally advanced cervical cancer in our center.

Materials and method

The clinical data of 93 patients with locally advanced cervical squamous cell cancer who received external beam radiotherapy (EBRT) combined with IGABT ± chemotherapy in our center were retrospectively analyzed. The disease stage, overall treatment time (OTT), chemotherapy, and the dose–volume parameters D₉₀, D₉₈, and D₁₀₀ of GTV_res, the intermediate-risk clinical target volume (CTV_IR), and the high-risk clinical target volume (CTV_HR) of the patients were statistically analyzed. Kaplan–Meier and uni- and multivariable Cox regression analyses were used to analyze 2‑year overall survival (OS), progression-free survival (PFS), and local control rate (LC). A probit model was employed to assess the dose–effect relationship between the volume and dose–volume parameters of GTV_res and 2‑year OS, PFS, and LC.

Results

The median follow-up time was 19.6 months and 2‑year OS, PFS, and LC were 79.6%, 68.8%, and 94.6%, respectively. CTV_HR D₉₀ was an independent influencing factor for 2‑year PFS (P = 0.041); GTV_resBT1 volume was an independent factor for 2‑year OS, PFS, and LC (P < 0.001). The probit model showed that at GTV_resBT1 volume < 32.86 cm³, the expected 2‑year LC was > 90%; at GTV_res D₉₈ > 129.12 Gy_EQD2, the expected 2‑year OS was > 90%.

Conclusion

Both the volume and dose–volume parameters of GTV_res are promising predictors in assessment of IGABT prognosis of cervical cancer.

Bethesda (2016) Prescribing, recording, and reporting brachytherapy for cancer of the cervix ICRU 89. J Int Comm Radiat Units Meas 13:1–2. https://doi.org/10.1093/jicru/ndw042CrossRef

Suneja G, Brown D, Chang A, Erickson B, Fidarova E, Grover S, Mahantshetty U, Nag S, Narayan K, Bvochora-Nsingo M, Viegas C, Viswanathan AN, Lin MY, Gaffney D (2017) American Brachytherapy Society: Brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries. Brachytherapy 16(1):85–94. https://doi.org/10.1016/j.brachy.2016.10.007CrossRef

Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, Petrow P, Rownd J, Kirisits C, GEC ESTRO Working Group (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77. https://doi.org/10.1016/j.radonc.2005.11.014CrossRef

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRef

Yoshida K, Jastaniyah N, Sturdza A, Lindegaard J, Segedin B, Mahantshetty U, Rai B, Jürgenliemk-Schulz I, Haie-Meder C, Sasaki R, Pötter R (2015) Assessment of parametrial response by growth pattern in patients with International Federation of Gynecology and Obstetrics stage IIB and IIIB cervical cancer: Analysis of patients from a prospective, multicenter trial (EMBRACE). Int J Radiat Oncol 93(4):788–796. https://doi.org/10.1016/j.ijrobp.2015.08.007CrossRef

Dimopoulos JC, Schard G, Berger D, Lang S, Goldner G, Helbich T, Pötter R (2006) Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: Potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. Int J Radiat Oncol Biol Phys 64(5):1380–1388. https://doi.org/10.1016/j.ijrobp.2005.10.017CrossRef

Viswanathan AN, Dimopoulos J, Kirisits C, Berger D, Pötter R (2007) Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys 68(2):491–498. https://doi.org/10.1016/j.ijrobp.2006.12.021CrossRef

Iwai Y, Nemoto MW, Horikoshi T, Kanazawa A, Kurokawa M, Saito M, Harada R, Kobayashi H, Uno T (2020) Comparison of CT-based and MRI-based high-risk clinical target volumes in image guided-brachytherapy for cervical cancer, referencing recommendations from the Japanese Radiation Oncology Study Group (JROSG) and consensus statement guidelines from the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC ESTRO). Jpn J Radiol 38(9):899–905. https://doi.org/10.1007/s11604-020-00980-yCrossRef

Minkoff D, Gill BS, Kang J, Beriwal S (2015) Cervical cancer outcome prediction to high-dose rate brachytherapy using quantitative magnetic resonance imaging analysis of tumor response to external beam radiotherapy. Radiother Oncol 115(1):78–83. https://doi.org/10.1016/j.radonc.2015.03.007CrossRef

10.

Dyk P, Jiang N, Sun B, DeWees TA, Fowler KJ, Narra V, Garcia-Ramirez JL, Schwarz JK, Grigsby PW (2014) Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging—Guided high-dose-rate and positron emission Tomography/computed Tomography—guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 90(4):794–801. https://doi.org/10.1016/j.ijrobp.2014.07.039CrossRef

11.

Pötter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jürgenliemk-Schulz I (2018) The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 9:48. https://doi.org/10.1016/j.ctro.2018.01.001CrossRef

12.

Kim YJ, Kim JY, Kim Y, Lim YK, Jeong J, Jeong C, Kim M, Lim MC, Seo SS, Park SY (2016) Magnetic resonance image-guided brachytherapy for cervical cancer: Prognostic factors for survival. Strahlenther Onkol 192(12):922–930. https://doi.org/10.1007/s00066-016-1049-xCrossRef

13.

Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R (2016) Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 120(3):441–446. https://doi.org/10.1016/j.radonc.2016.05.014CrossRef

14.

Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL (2019) Cervical cancer, version 3.2019. J Natl Compr Cancer Netw 17(1):64–84. https://doi.org/10.6004/jnccn.2019.0001CrossRef

15.

Dimopoulos JC, Lang S, Kirisits C, Fidarova EF, Berger D, Georg P, Dörr W, Pötter R (2009) Dose-volume histogram parameters and local tumor control in MR image guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 75(1):56–63. https://doi.org/10.1016/j.ijrobp.2008.10.033CrossRef

16.

Villafranca E, Navarrete P, Sola A, Muruzabal JC, Aguirre S, Ostiz S, Sanchez C, Guarch R, Lainez N, Barrado M (2018) Image-guided brachytherapy in cervical cancer: Experience in the Complejo Hospitalario de Navarra. Rep Pract Oncol Radiother 23(6):510–516. https://doi.org/10.1016/j.rpor.2018.09.006CrossRef

17.

Mazeron R, Castelnau-Marchand P, Dumas I, del Campo ER, Kom LK, Martinetti F, Farha G, Tailleur A, Morice P, Chargari C, Lefkopoulos D, Haie-Meder C (2015) Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulseddose rate adaptive brachytherapy. Radiother Oncol 114(2):257–263. https://doi.org/10.1016/j.radonc.2014.11.045CrossRef

18.

Chargari C, Mazeron R, Dunant A, Gouy S, Petit C, Maroun P, Uzan C, Annede P, Bentivegna E, Balleyguier C, Genestie C, Pautier P, Leary A, Lhomme C, Deutsch E, Morice P, Haie-Meder C (2016) Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. Clin Exp Metastasis 33(8):775–785. https://doi.org/10.1007/s10585-016-9817-7CrossRef

19.

Schernberg A, Bockel S, Annede P, Fumagalli I, Escande A, Mignot F, Kissel M, Morice P, Bentivegna E, Gouy S, Deutsch E, Haie-Meder C, Chargari C (2018) Tumor shrinkage during chemoradiation in locally advanced cervical cancer patients: prognostic significance, and impact for image-guided adaptive brachytherapy. Int J Radiat Oncol Biol Phys 102(3):220–S221. https://doi.org/10.1016/j.ijrobp.2018.06.014CrossRef

20.

Petrič P, Hudej R, Rogelj P, Blas M, Tanderup K, Fidarova E, Kirisits C, Berger D, Dimopoulos JC, Pötter R, Hellebust TP (2013) Uncertainties of target volume delineation in MRI guided adaptive brachytherapy of cervix cancer: A multi-institutional study. Radiother Oncol 107(1):6–12. https://doi.org/10.1016/j.radonc.2013.01.014CrossRef

21.

Han K, Croke J, Foltz W, Metser U, Xie J, Shek T, Driscoll B, Ménard C, Vines D, Coolens C, Simeonov A, Beiki-Ardakani A, Leung E, Levin W, Fyles A, Milosevic MF (2016) A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiother Oncol 120(3):519–525. https://doi.org/10.1016/j.radonc.2016.08.002CrossRef

Titel: Dose–effect relationship between dose–volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study
verfasst von: Tianyang Ke
Jinbao Wang
Ning Zhang
Hongfu Zhao
Xin Guo
Zhipeng Zhao
Zhuang Mao
Guanghui Cheng
Publikationsdatum: 15.09.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 2/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-02000-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Dose–effect relationship between dose–volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study

Abstract

Purpose

Materials and method

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

CircDLG1 promotes malignant development of non-small cell lung cancer through regulation of the miR-630/CENPF axis

Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival

Stereotactic body radiotherapy for recurrent hemoptysis due to chronic pulmonary aspergillosis: a case report and systematic review of the literature

Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis

26th Annual SASRO Meeting

Proton and carbon ion beam treatment with active raster scanning method in 147 patients with skull base chordoma at the Heidelberg Ion Beam Therapy Center—a single-center experience

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie